Free Trial
→ College grad makes $64,000 a month (From Stansberry Research) (Ad)tc pixel Free RPRX Stock Alerts

Royalty Pharma (RPRX) Stock Forecast & Price Target

Royalty Pharma logo
$36.36 -0.34 (-0.93%)
Closing price 04:00 PM Eastern
Extended Trading
$36.24 -0.13 (-0.34%)
As of 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Royalty Pharma - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Buy
Based on 3 Analyst Ratings
Sell
0
Hold
0
Buy
3

Based on 3 Wall Street analysts who have issued ratings for Royalty Pharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 2 have given a buy rating, and 1 has given a strong buy rating for RPRX.

Consensus Price Target

$48.00
32.01% Upside
According to the 3 analysts' twelve-month price targets for Royalty Pharma, the average price target is $48.00. The highest price target for RPRX is $54.00, while the lowest price target for RPRX is $42.00. The average price target represents a forecasted upside of 32.01% from the current price of $36.36.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for RPRX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Royalty Pharma and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RPRX Analyst Ratings Over Time

TypeCurrent Forecast
9/12/24 to 9/12/25		1 Month Ago
8/13/24 to 8/13/25		3 Months Ago
6/14/24 to 6/14/25		1 Year Ago
9/13/23 to 9/12/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$48.00$49.00$47.33$42.00
Forecasted Upside32.01% Upside34.39% Upside35.86% Upside52.45% Upside
Consensus RatingBuyBuyBuyModerate Buy

RPRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RPRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Royalty Pharma Stock vs. The Competition

TypeRoyalty PharmaMedical CompaniesS&P 500
Consensus Rating Score
3.33
2.78
2.53
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside30.79% Upside17,119.03% Upside9.66% Upside
News Sentiment Rating
Positive News

See Recent RPRX News
Positive News
Positive News
Export to Excel
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
7/22/2025Citigroup
2 of 5 stars
Geoff Meacham
Geoff Meacham
Not Rated
Boost TargetBuy$40.00 ➝ $42.00+17.86%
7/10/2025Morgan Stanley
3 of 5 stars
Terence Flynn
Terence Flynn
Not Rated
Boost TargetOverweight$51.00 ➝ $54.00+49.25%
12/24/2024TD Cowen
4 of 5 stars
M. Nedelcovych
Not Rated
UpgradeStrong-Buy
8/14/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Boost TargetBuy$50.00 ➝ $51.00+89.87%
6/3/2024UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 DowngradeBuy ➝ Neutral$28.00+2.83%
4/12/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Lower TargetBuy$40.00 ➝ $38.00+30.81%
2/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Lower TargetOverweight$45.00 ➝ $42.00+39.21%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:43 PM ET.


Should I Buy Royalty Pharma Stock? RPRX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 10, 2025. Please send any questions or comments about these Royalty Pharma pros and cons to contact@marketbeat.com.

Royalty Pharma
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Royalty Pharma plc:

  • The stock has recently been upgraded to a "buy" rating by multiple analysts, indicating positive sentiment and potential for growth.
  • Royalty Pharma plc has a strong market capitalization of over $21 billion, suggesting stability and investor confidence.
  • The current stock price is around $36, which is near its 12-month high, reflecting strong performance in the market.
  • The company reported earnings per share (EPS) of $1.14, exceeding expectations, which demonstrates its profitability and operational efficiency.
  • Royalty Pharma plc has declared a quarterly dividend of $0.22 per share, providing a yield of 2.4%, which can be attractive for income-focused investors.

Royalty Pharma
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Royalty Pharma plc for these reasons:

  • The company reported revenue of $578.67 million, which fell short of analysts' expectations, indicating potential challenges in meeting growth targets.
  • Despite a solid EPS, the price-to-earnings (P/E) ratio is around 20.85, which may suggest that the stock is overvalued compared to its earnings.
  • The stock has experienced fluctuations, with a 12-month low of $24.05, indicating volatility that could concern risk-averse investors.
  • The debt-to-equity ratio of 0.74 suggests that the company has a moderate level of debt, which could impact financial stability in adverse conditions.
  • Analysts have set a consensus price target of $48, which may indicate limited upside potential from the current price level.

RPRX Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Royalty Pharma is $48.00, with a high forecast of $54.00 and a low forecast of $42.00.

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last twelve months. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RPRX shares.

According to analysts, Royalty Pharma's stock has a predicted upside of 32.01% based on their 12-month stock forecasts.

Royalty Pharma has been rated by research analysts at Citigroup, and Morgan Stanley in the past 90 days.

Analysts like Royalty Pharma more than other "medical" companies. The consensus rating for Royalty Pharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RPRX compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NASDAQ:RPRX) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsoredtc pixel
Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...
Paradigm Press | Sponsoredtc pixel
Forget NVDA. Put $1,000 into this stock now
A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...
Chaikin Analytics | Sponsoredtc pixel
6-Figure Target for BTC by 2025
Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...
Crypto 101 Media | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
IRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...
American Alternative | Sponsoredtc pixel
Do NOT Day Trade (Do THIS instead)
Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...
Monument Traders Alliance | Sponsoredtc pixel
The $17B signal no one expected…
After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...
Brownstone Research | Sponsoredtc pixel